A peer-review study by Optibrium has demonstrated the value of deep learning for imputation of drug discovery data.
The Cambridge, UK-based based software and services provider for drug discovery published ‘Practical Applications of Deep Learning to Impute Heterogeneous Drug Discovery Data’ in the Journal of Chemical Information and Modeling.
According to the company, the paper is testament to the unique ability of the Alchemite deep learning algorithm to extract additional value from experimental data in the context of an evolving drug discovery project.
In collaboration with the clinical-stage biopharmaceutical company, Constellation Pharmaceuticals, and technology partner Intellegens, Optibrium’s Augmented Chemistry technologies were demonstrated to more accurately guide compound optimisation to target high-quality compounds.
The study showed that, whereas conventional quantitative structure-activity relationship methods struggle with the inherently noisy and sparse experimental data in drug discovery, the Augmented Chemistry platform, powered by Intellegens’ Alchemite method, provides robust, high-quality predictions.
Its ability to exploit correlations between different measurements and explicitly estimate uncertainties in each prediction enables confident decision-making to prioritise experimental work and expedite drug discovery project cycles.
Optibrium’s Augmented Chemistry family of innovative products and services enhance decision making in drug discovery using Artificial Intelligence technologies. These supplement project scientists’ experience and skills by learning from all available data, updated continuously with the latest data generated in discovery project iterations.
Having demonstrated the value of the Augmented Chemistry platform in many successful collaborations with global pharma and biotech companies, Optibrium is releasing this ground-breaking technology as a deployable product that will support and enhance pharmaceutical research and development.
“The fact that each prediction was provided with a confidence level opened up substantial opportunities for our projects. For example, this study demonstrated that we could have avoided synthesising at least 10% of the compounds in our discovery project,” said Julian Levell, Vice President of Drug Discovery at Constellation Pharmaceuticals.
“Those compounds predicted to be inactive with high confidence, were confirmed to be inactive – with a negligible rate of false negatives. Furthermore, some experimental data were flagged up as outliers based on these confidence levels.
“Investigating these data points further confirmed that many were measured false negatives in assays and potentially missed opportunities or missed liabilities. Overall, the Augmented Chemistry platform brings something truly new to the table.”
Matthew Segall, Optibrium’s CEO, added: “The truly outstanding results corroborate the tremendous potential we have seen in joint projects with other pharmaceutical companies and biotechs, and we are excited to be releasing Augmented Chemistry products later this year to make this technology widely available.”
The companies continue to work closely together to leverage future opportunities to advance their respective projects and invest in the innovative technologies that enhance their work.